Active TMS for Age-associated Memory Impairment

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Shirley Ryan AbilityLab, Chicago, IL
Age-associated Memory Impairment
Transcranial Magnetic Stimulation (TMS) Cone Coil - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The aim of this study is to investigate the effects of Transcranial Magnetic Stimulation (TMS) following a Paired Associative Stimulation (PAS) protocol on the memorization capacity of elderly individuals. For this purpose, we will apply TMS synchronized with a working memory (WM) task and assess its effects on cortical connectivity and memorization capacity by Magnetic Resonance Imaging (MRI) and WM task learning. This study will be carried out in an older population of healthy participants. We will use the study results to refine the task related PAS protocol towards enhancing memory performance and brain connectivity.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Compared during each visit between baseline, immediately after the intervention, and 30 minutes after intervention

Compared during each visit between baseline and 30 minutes after intervention
Changes in resting state functional MRI connectivity
Compared during each visit between baseline, immediately after the intervention, and 30 minutes after intervention
Changes in Working Memory (WM) capacity

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Active TMS
1 of 2
Sham TMS
1 of 2
Experimental Treatment
Non-Treatment Group

20 Total Participants · 2 Treatment Groups

Primary Treatment: Active TMS · Has Placebo Group · Phase < 1

Active TMS
Device
Experimental Group · 1 Intervention: Transcranial Magnetic Stimulation (TMS) Cone Coil · Intervention Types: Device
Sham TMS
Device
ShamComparator Group · 1 Intervention: Transcranial Magnetic Stimulation (TMS) Sham Coil · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: compared during each visit between baseline, immediately after the intervention, and 30 minutes after intervention

Trial Background

Jose Pons, Principal Investigator
Principal Investigator
Shirley Ryan AbilityLab
Closest Location: Shirley Ryan AbilityLab · Chicago, IL
Photo of Chicago  1Photo of Chicago  2Photo of Chicago  3
2022First Recorded Clinical Trial
1 TrialsResearching Age-associated Memory Impairment
30 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no history of a brain or skull lesion.
You have normal vision.\n
You are able to understand and speak English.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.